Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11531019 | 0.87 | ALDH1A1 (0.44) | RAB9ANPC1GFERKDM4ESMN1; SMN2 | |
| SCHEMBL11158867 | 0.84 | MEN1 (0.47) | RAB9ANPC1GFERTRPM8KDM4E | |
| SCHEMBL4600718 | 0.83 | CYP4F2 (0.50) | NPC1TRPM8KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL687742 | 0.82 | ALDH1A1 (0.49) | RAB9ANPC1GFERKDM4ESMN1; SMN2 | |
| SCHEMBL9031656 | 0.81 | MAPT (0.46) | SMN1; SMN2ALDH1A1RECQLMAPT | |
| SCHEMBL11206210 | 0.81 | NPSR1 (0.44) | RAB9ANPC1GFERKDM4ESMN1; SMN2 | |
| SCHEMBL29020269 | 0.81 | ALDH1A1 (0.60) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL11531240 | 0.78 | TSHR (0.53) | RAB9ANPC1GFERKDM4ESMN1; SMN2 | |
| SCHEMBL11442379 | 0.77 | POLB (0.37) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL23647729 | 0.77 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2ALDH1A1RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0023938-B1 | PREPARATION OF PYRROLE-2-ACETATES | McNeilab, Inc. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0023938-A1 | Preparation of pyrrole-2-acetates | McNeilab, Inc. (US) | 1981-02-18 | — | — | EP | claimed |
| US-4216150-A | Preparation of pyrrole-2-acetates | MCNEIL LAB, INC. (US) | 1980-08-05 | — | — | US | claimed |
| US-4207237-A | Preparation of pyrrole-2-acetates | MCNEILAB, INC. (US) | 1980-06-10 | — | — | US | claimed |
| US-4187230-A | Preparation of 5-aroyl-pyrrole compounds | ETHYL CORPORATION (US) | 1980-02-05 | — | — | US | claimed |
| CN-112661688-B | Synthetic method of non-steroidal anti-inflammatory drug tolmetin | 杭州迪克科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-5721347-A | Esters and amides of substituted pyrrole acetic acids | CELL PATHWAYS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0714895-A1 | Pyrrole derivatives | F. Hoffmann-La Roche AG (CH) | 1996-06-05 | — | — | EP | disclosed |
| US-4216150-A | Preparation of pyrrole-2-acetates | MCNEIL LAB, INC. (US) | 1980-08-05 | — | — | US | disclosed |
| US-4207237-A | Preparation of pyrrole-2-acetates | MCNEILAB, INC. (US) | 1980-06-10 | — | — | US | disclosed |
| EP-0010553-A1 | Process of reducing a loweralkyl 1-loweralkyl-pyrrole-2-glyoxylate to a loweralkyl 1-loweralkyl-pyrrole-2-acetate | McNeilab, Inc. (US) | 1980-05-14 | — | — | EP | disclosed |
| US-4136097-A | COPPER(II) COMPLEX AS PROMOTER | MCNEIL LABORATORIES, INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4125537-A | REDUCTION OF PYRROLE-2-GLYOXYLATES AMINE CATALYZED ACTION OF HYDROGEN SULFIDE IN TERTIARY AMINE SOLVENT | MCNEIL LABORATORIES, INCORPORATED (US) | 1978-11-14 | — | — | US | disclosed |
| US-3957818-A | PREPARATION OF PYRROLE-2-ACETIC ACID DERIVATIVES | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-05-18 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
| US-3950355-A | 5-CHLOROCARBONYL | MCNEIL LABORATORIES, INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | RAB9A 4329/4885NPC1 1644/4885GFER 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.